title: Preliminary study of beta-blocker therapy on modulation of interleukin-33/ST2 signaling during ventricular remodeling after acute myocardial infarction.
abstract: BACKGROUND
  This study aimed to evaluate the role of b-blocker therapy on modulating interleukin (IL)-33/ST2 (interleukin-1 receptor-like 1) signaling during ventricular remodeling related to heart failure (HF) after acute myocardial infarction (AMI).
  
  
  METHODS
  Sprague-Dawley rats that survived surgery to induce AMI were randomly divided into the placebo group and the b-blocker treatment group. A sham group was used as a control. Left ventricular (LV) function variables, the myocardial infarct size, fibrosis and IL-33/ST2 protein expression was measured.
  
  
  RESULTS
  Compared with the placebo group, b-blocker treatment significantly improved LV function and reduced infarct size (p < 0.05). There was higher protein expression of IL-33 (p < 0.05) and sST2 (p < 0.05), as well as higher expression of fibrosis (p < 0.05), compared to the sham group. Notably, the high expression of cardioprotective IL-33 was not affected by b-blocker treatment (p > 0.05), however, treatment with b-blocker enhanced IL-33/ST2 signaling, with lower expression of sST2 (p < 0.05) and significantly attenuated fibrosis (p < 0.05).
  
  
  CONCLUSIONS
  Our study suggested that b-blocker therapy might play a beneficial role in the modula-tion of IL-33/ST2 signaling during ventricular remodeling. These results may be helpful in identifying IL-33/ST2 systems as putative b-blocker targets at an early stage after AMI. (Cardiol J 2017; 24, 2: 188-194).
authors.affiliation: Xuanwu Hospital, Capital Medical University. xudheart@aliyun.com.
authors.forename: Jinggang
authors.initials: J
authors.lastname: Xia
authors.forename: Yang
authors.initials: Y
authors.lastname: Qu
authors.forename: Chunlin
authors.initials: C
authors.lastname: Yin
authors.forename: Dong
authors.initials: D
authors.lastname: Xu
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D000067596:Interleukin-33 / Q000378:metabolism*; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017472:Receptors, Interleukin-1 / Q000378:metabolism*; D015398:Signal Transduction; D015854:Up-Regulation / Q000187:drug effects*; D016277:Ventricular Function, Left / Q000187:drug effects / Q000502:physiology*; D020257:Ventricular Remodeling / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; C553108:Il33 protein, rat; D000067596:Interleukin-33; D017472:Receptors, Interleukin-1; C000589812:ST2 protein, rat
keywords: IL-33/ST2; acute myocardial infarction; beta-blocker; ventricular remodeling